[The longest clinical study of Smeglutide was published: it can maintain a weight loss of 10% after four years of medication] Star weight loss therapy Smeglutide manufacturer Novo Nordisk displayed the longest clinical follow-up data of the company so far at the European Obesity Conference on May 14, local time. The results showed that overweight and obese patients with heart disease but no diabetes could still maintain an average weight loss of 10% after four years of continuous treatment with Wegovy, a weight loss drug of Smeglutide.